Peer-reviewed evidence.

Understanding the evidence.

The evidence base for HMSC-derived exosome biologics spans the full hierarchy of research design. At the top of that hierarchy sit randomised controlled trials (RCTs) and systematic reviews, which provide the most rigorous assessment of safety and preliminary efficacy. Below these are controlled clinical studies, case series, preclinical animal models, and in vitro laboratory experiments. Each level contributes differently to the overall picture - preclinical work establishes biological plausibility, while clinical data tests whether that plausibility translates to human outcomes.

The strongest evidence domains currently are pulmonary applications, where a Phase 2 double-blind RCT (CHEST 2023) has demonstrated statistically significant outcomes in ARDS management with zero treatment-related adverse events, and dermatological applications, where a systematic review of 11 clinical studies including 2 RCTs (PMC 2025) has quantified hair density improvements across alopecia types. The global safety profile is further supported by a comprehensive NIH meta-analysis (2024) reporting a 0.7% serious adverse event rate across all completed extracellular vesicle clinical trials. Neurological applications, while supported by strong preclinical evidence and plausible biological mechanisms, remain at an earlier translational stage.

It is essential to note that all products referenced on this page remain investigational. No exosome biologic has received regulatory approval as a therapeutic product in any jurisdiction - including the FDA, EMA, and TGA. Research indicates promising signals across multiple domains, but promising signals are not equivalent to established clinical proof. Practitioners evaluating these biologics should assess the evidence level appropriate to each application and assume full regulatory responsibility for any clinical use. For a comprehensive domain-by-domain review, see the full evidence review article.